Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations in non–small-cell lung cancer predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs). EGFR mutation types are associated with efficacy of EGFR TKIs. We investigated the clinical outcomes of afatinib, erlotinib, and gefitinib accord...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sojung, Lee, Sung Yong, Kim, Dojin, Sim, Yun Su, Ryu, Jeong-Seon, Choi, Juwhan, Lee, Su Hwan, Ryu, Yon Ju, Lee, Jin Hwa, Chang, Jung Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802134/
https://www.ncbi.nlm.nih.gov/pubmed/33430803
http://dx.doi.org/10.1186/s12885-020-07765-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802134/
https://www.ncbi.nlm.nih.gov/pubmed/33430803
http://dx.doi.org/10.1186/s12885-020-07765-6

Ejemplares similares